CN106083873A - 一种l‑苯丙氨酸取代去甲斑蝥素衍生物及其制备方法与应用 - Google Patents
一种l‑苯丙氨酸取代去甲斑蝥素衍生物及其制备方法与应用 Download PDFInfo
- Publication number
- CN106083873A CN106083873A CN201610539747.3A CN201610539747A CN106083873A CN 106083873 A CN106083873 A CN 106083873A CN 201610539747 A CN201610539747 A CN 201610539747A CN 106083873 A CN106083873 A CN 106083873A
- Authority
- CN
- China
- Prior art keywords
- ring substituent
- phenylalanine
- substituent norcantharidin
- phenylalanine ring
- chromone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 L phenylalanine ring substituent norcantharidin derivative Chemical class 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- JAABVEXCGCXWRR-FBXFSONDSA-N rel-norcantharidin Chemical group C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 claims abstract description 16
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 15
- 125000001424 substituent group Chemical group 0.000 claims abstract description 14
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 14
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 13
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical group C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 7
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- XLVXXKZBDHWNMK-UHFFFAOYSA-N N-[(6-bromochromen-4-ylidene)amino]aniline Chemical compound C1(=CC=CC=C1)NN=C1C=COC2=CC=C(C=C12)Br XLVXXKZBDHWNMK-UHFFFAOYSA-N 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 7
- 208000035126 Facies Diseases 0.000 claims description 6
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 claims description 6
- 229940067157 phenylhydrazine Drugs 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- XVNBWGGBXOJIDR-UHFFFAOYSA-N 6-bromochromen-4-one Chemical compound O1C=CC(=O)C2=CC(Br)=CC=C21 XVNBWGGBXOJIDR-UHFFFAOYSA-N 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 3
- 238000005698 Diels-Alder reaction Methods 0.000 claims description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 230000018044 dehydration Effects 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 230000003292 diminished effect Effects 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000002808 molecular sieve Substances 0.000 claims description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 3
- 239000012265 solid product Substances 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims 1
- 238000007259 addition reaction Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000011049 filling Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000007984 tetrahydrofuranes Chemical class 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 11
- 230000001629 suppression Effects 0.000 abstract description 6
- 201000007270 liver cancer Diseases 0.000 abstract description 5
- 208000014018 liver neoplasm Diseases 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 210000004881 tumor cell Anatomy 0.000 abstract description 5
- 241001597008 Nomeidae Species 0.000 abstract description 4
- 125000003226 pyrazolyl group Chemical group 0.000 abstract description 4
- 150000003217 pyrazoles Chemical class 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000003993 interaction Effects 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960005190 phenylalanine Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- HPPYHLAUVVJOLY-UHFFFAOYSA-N 2-bromochromen-4-one Chemical compound C1=CC=C2OC(Br)=CC(=O)C2=C1 HPPYHLAUVVJOLY-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000004777 chromones Chemical class 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 1
- 229940095758 cantharidin Drugs 0.000 description 1
- 229930008397 cantharidin Natural products 0.000 description 1
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610539747.3A CN106083873B (zh) | 2016-07-06 | 2016-07-06 | 一种l-苯丙氨酸取代去甲斑蝥素衍生物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610539747.3A CN106083873B (zh) | 2016-07-06 | 2016-07-06 | 一种l-苯丙氨酸取代去甲斑蝥素衍生物及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106083873A true CN106083873A (zh) | 2016-11-09 |
CN106083873B CN106083873B (zh) | 2018-07-17 |
Family
ID=57212787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610539747.3A Active CN106083873B (zh) | 2016-07-06 | 2016-07-06 | 一种l-苯丙氨酸取代去甲斑蝥素衍生物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106083873B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107602578A (zh) * | 2017-11-07 | 2018-01-19 | 绍兴文理学院 | 一种含哒嗪酮结构的d‑缬氨酸取代去甲斑蝥素衍生物的制备方法及其应用 |
CN107759611A (zh) * | 2017-11-07 | 2018-03-06 | 绍兴文理学院 | 一种含哒嗪酮结构的l‑苯丙氨酸取代去甲斑蝥素衍生物的制备方法及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002076989A1 (en) * | 2001-03-23 | 2002-10-03 | The University Of Newcastle Research Associates Limited | Protein phosphate inhibitors |
CN103554122A (zh) * | 2013-11-15 | 2014-02-05 | 绍兴文理学院 | 一种含色酮结构吡唑类去甲斑蝥素衍生物及其制备方法与应用 |
CN103554123A (zh) * | 2013-11-15 | 2014-02-05 | 绍兴文理学院 | 含色酮结构吡唑类去甲斑蝥素衍生物及其制备方法与应用 |
CN103896954A (zh) * | 2013-11-15 | 2014-07-02 | 绍兴文理学院 | 一种吡唑类去甲斑蝥素衍生物及其制备方法与应用 |
-
2016
- 2016-07-06 CN CN201610539747.3A patent/CN106083873B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002076989A1 (en) * | 2001-03-23 | 2002-10-03 | The University Of Newcastle Research Associates Limited | Protein phosphate inhibitors |
CN103554122A (zh) * | 2013-11-15 | 2014-02-05 | 绍兴文理学院 | 一种含色酮结构吡唑类去甲斑蝥素衍生物及其制备方法与应用 |
CN103554123A (zh) * | 2013-11-15 | 2014-02-05 | 绍兴文理学院 | 含色酮结构吡唑类去甲斑蝥素衍生物及其制备方法与应用 |
CN103896954A (zh) * | 2013-11-15 | 2014-07-02 | 绍兴文理学院 | 一种吡唑类去甲斑蝥素衍生物及其制备方法与应用 |
Non-Patent Citations (6)
Title |
---|
DA-FENG CHEN ET AL.: "Improved synthesis and characterization of L-histidine norcantharimide, a novel potent protein phosphatase 2A inhibitor", 《JOURNAL OF CHINESE PHARMACEUTICAL SCIENCES》 * |
DENG LIPING ET AL.: "Mass spectra of novel 5,6-dehydronorcantharidin derivatives substituted by aromatic amine", 《JOURNAL OF SHAOXING UNIVERSITY》 * |
田少雷等: "抗肿瘤药物研究I : 去甲斑鳌素氨基酸衍生物的合成与抗癌活性", 《药学学报》 * |
邓莉平等: "新型吡唑去甲斑蝥酰亚胺衍生物的核磁共振波谱分析", 《绍兴文理学院学报》 * |
黄文盈等: "新型含色酮异噁唑类去甲斑蝥衍生物的合成", 《绍兴文理学院学报》 * |
黄永华等: "去甲基斑蝥素衍生物的合成,碘-125标记及在动物体内的分布", 《合成化学》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107602578A (zh) * | 2017-11-07 | 2018-01-19 | 绍兴文理学院 | 一种含哒嗪酮结构的d‑缬氨酸取代去甲斑蝥素衍生物的制备方法及其应用 |
CN107759611A (zh) * | 2017-11-07 | 2018-03-06 | 绍兴文理学院 | 一种含哒嗪酮结构的l‑苯丙氨酸取代去甲斑蝥素衍生物的制备方法及其应用 |
CN107602578B (zh) * | 2017-11-07 | 2019-07-16 | 绍兴文理学院 | 一种含哒嗪酮结构的d-缬氨酸取代去甲斑蝥素衍生物的制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106083873B (zh) | 2018-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106397445B (zh) | 含有色酮结构的吡唑类n-对溴苯基马来酰亚胺衍生物及其制备方法与应用 | |
CN107674083B (zh) | 一种含哒嗪酮结构的l-亮氨酸取代去甲斑蝥素衍生物的制备方法及其应用 | |
CN103554122A (zh) | 一种含色酮结构吡唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN106083873A (zh) | 一种l‑苯丙氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN106188080B (zh) | 一种d-苯丙氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN106220642B (zh) | 一种l-亮氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN106083884A (zh) | 一种d‑亮氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN106188081B (zh) | 一种d-缬氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN106046019B (zh) | 一种l-缬氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN108623604B (zh) | 一种d-苯丙氨酸取代马来酰亚胺衍生物及其制备方法与应用 | |
CN105906633B (zh) | 含有色酮结构的吡唑类n‑苯基马来酰亚胺衍生物及其制备方法与应用 | |
CN107674082B (zh) | 一种含哒嗪酮结构的d-苯丙氨酸取代去甲斑蝥素衍生物的制备方法及其应用 | |
CN107759611B (zh) | 一种含哒嗪酮结构的l-苯丙氨酸取代去甲斑蝥素衍生物的制备方法及其应用 | |
CN107722029B (zh) | 一种含哒嗪酮结构的d-亮氨酸取代去甲斑蝥素衍生物的制备方法及其应用 | |
CN107602578B (zh) | 一种含哒嗪酮结构的d-缬氨酸取代去甲斑蝥素衍生物的制备方法及其应用 | |
CN105924445B (zh) | 含有色酮结构的吡唑类n‐对硝基苯基马来酰亚胺衍生物及其制备方法与应用 | |
CN105859724B (zh) | 3‑(6‑溴‑4‑氧‑4H‑色酮)‑1‑苯基‑5‑对氯苯基‑1,6a‑二氢吡咯啉[3,4‑c]吡唑‑4,6(3aH,5H)‑二酮及其制备方法与应用 | |
CN105906634A (zh) | 3-(6-溴-4-氧-4H-色酮)-1-苯基-5-对甲氧基苯基-1,6a-二氢吡咯啉[3,4-c]吡唑-4,6(3aH,5H)-二酮及其制备方法与应用 | |
CN108727383B (zh) | 一种l-苯丙氨酸取代马来酰亚胺衍生物及其制备方法与应用 | |
CN105906632A (zh) | 含有色酮结构的吡唑类n-对甲苯基马来酰亚胺衍生物及其制备方法与应用 | |
CN110105364A (zh) | 含吡唑结构N-对氯苯基取代马来酰亚胺α-松油烯环加成衍生物及其制备方法和应用 | |
CN109988178A (zh) | 含吡唑结构N-对硝基苯基取代马来酰亚胺α-松油烯环加成衍生物及其制备方法和应用 | |
CN108752306B (zh) | 6-氟-1,3-二羟基氧杂蒽酮及其制备方法和应用 | |
CN108997300B (zh) | 7,8-二氟-1,3-二羟基氧杂蒽酮及其制备方法和应用 | |
CN109988176A (zh) | 含吡唑结构N-对溴苯基取代马来酰亚胺α-松油烯环加成衍生物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191128 Address after: Room 314-1, dantaihu building (Wuluo Science Park), No.9, Taihu East Road, Wuzhong District, Suzhou, Jiangsu Province Patentee after: Suzhou ruipengcheng Technology Co.,Ltd. Address before: 312000, No. 508 West Ring Road, Yuecheng District, Zhejiang, Shaoxing Patentee before: Shaoxing University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230819 Address after: Room 2101, 2102, 2105, and 2106, Building 2, Ruixin Enterprise Plaza (formerly known as "Cross border E-commerce Industrial Park"), No. 67 Jinzhou Avenue, High tech Development Zone, Changsha City, Hunan Province, 410000 Patentee after: Hunan Shangzhonghe Biopharmaceutical Co.,Ltd. Address before: Room 314-1, dantaihu building (Wuluo Science Park), No.9, Taihu East Road, Wuzhong District, Suzhou City, Jiangsu Province, 215100 Patentee before: Suzhou ruipengcheng Technology Co.,Ltd. |
|
TR01 | Transfer of patent right |